Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers
24 de outubro de 2016 atualizado por: Meredith Rowe, University of South Florida
The purpose of the study is to determine whether a combined intervention of a night home monitoring system and cognitive-behavioral therapy for insomnia (CBTi) is effective in improving sleep in dementia caregivers who arise at night.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
Informal caregivers provide the majority of care for chronically ill adults, including persons with dementia.
While these individuals provide a great benefit to the chronically ill relative, being a caregiver is associated with deleterious health consequences, including premature mortality and higher rates of coronary heart disease (CHD).
Another common complaint among dementia caregivers is poor sleep, which has been connected to premature mortality and higher rates of CHD in noncaregiving adults.
Currently no sleep therapies are empirically validated as effective for caregivers of persons with dementia (PWD), and since PWD often arise at night, improving caregiver sleep could be potentially hazardous as a sleeping caregiver cannot provide supervision during night awakenings.
Our primary purpose is thus to determine whether a combined intervention is effective in improving sleep in caregivers of PWD who arise at night.
The intervention consists of a night home monitoring system that provides reliable alerts to caregivers when PWD leave the bed and move through the house.
While this system improved home safety for PWD, it did not affect caregiver sleep, so a more traditional sleep therapy will be added-cognitive-behavioral therapy for insomnia.
In the proposed study, experimental participants will receive the night home monitoring system + CBTi; active comparator participants will receive the night home monitoring system and sleep behavioral therapy.
Participants will remain in the study for 29 weeks, with 4 data collection points.
We hypothesize experimental participants will have less time awake after going to bed, and improved sleep efficiency (percent time asleep while in bed).
Sleep data will be collected for multiple nights using actigraphy and sleep diary.
Our secondary research questions focus on the relationship between poor sleep and CHD.
Both in adults and in dementia caregivers, there appears to be a link between poor sleep and abnormal levels on coronary heart disease biomarkers, and likely an increase in CHD with poor sleep.
We aim to further explore this relationship as well as determine whether levels of biomarkers improve with improved sleep from the intervention.
We propose to draw blood samples at 4 data collection points and measure a set of biomarkers indicative of CHD.
Tipo de estudo
Intervencional
Inscrição (Real)
80
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- University Of South Florida
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
21 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Primary caregiver for a relative who has been diagnosed by a physician with dementia or Alzheimer's disease.
- Persons with dementia sleep in the same location each night.
- Caregiver provides care for persons with dementia with nighttime activity that occurs at least one night/week.
- Caregiver meets the standard criteria for Insomnia.
- Caregiver sleep problems affect daytime functioning.
- If caregiver uses sleep medication, dose stable for 6 months.
- Caregiver Telephone Interview for Cognitive Status Score > 25.
- Caregiver does not require assistive devices to walk in the home at night.
Exclusion Criteria:
- Caregiver receives respite care at night the majority of the time.
- Caregiver has diagnosed sleep disorder.
- Caregiver uses CPAP at night
- Caregiver has chronic illness that requires frequent, weekly treatment/assessment by a healthcare provider.
- Current use of anticoagulant medication by the caregiver.
- Caregiver Sleep Apnea-Hypopnea Index (AHI) score > 10 or > 15 if pulse oximetry ≥ 88%.
- Caregiver shows evidence of Restless Leg Syndrome per the Cambridge-Hopkins Restless Leg Syndrome Questionnaire.
- Montreal Cognitive Assessment (MOCA) score < 26.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sleep Behavioral Therapy A and NHMS
Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
|
The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night. Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments. |
|
Comparador Ativo: Sleep Behavioral Therapy B and NHMS
Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
|
The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night. Sleep behavioral therapy B uses primarily behavioral adjustments. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Wake Time (TWT)
Prazo: Week 27-28
|
Actigraphy, using the Actiwatch2, will be used to measure objective sleep; We will collect data for 14-day periods using a 30-second epoch length to accurately capture night-to-night variability. Subjects will also complete a sleep diary for each day of actigraphic data collection, which will provide subjective sleep values of TWT. Data collected include bedtime, sleep start, number awakenings, minutes awake during night, wake time, out-of-bed time, minutes spent napping the previous day, and a sleep quality rating. |
Week 27-28
|
|
Sleep Efficiency (SE)
Prazo: Week 27-28
|
Actigraphy, using the Actiwatch2, will be used to measure objective sleep; We will collect data for 14-day periods using a 30-second epoch length to accurately capture night-to-night variability. Subjects will also complete a sleep diary for each day of actigraphic data collection, which will provide subjective sleep values of SE. Data collected include bedtime, sleep start, number awakenings, minutes awake during night, wake time, out-of-bed time, minutes spent napping the previous day, and a sleep quality rating. |
Week 27-28
|
|
Nighttime Injuries
Prazo: Week 27-28
|
The Caregiver will be asked about any PWD injuries that occurred since the last data collection point.
Injuries will be coded according to the American National Standards method of recording injuries.
The following data are collected: nature of injury; part of the body affected; object, substance, exposure, or bodily motion that caused the injury; event that directly resulted in the injury; and time and place of the injury's occurrence.
An injury will be considered nighttime if the caregiver reported being asleep at the time the injury occurred.
|
Week 27-28
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
D-Dimer Levels
Prazo: Week 27
|
D-Dimer is a marker of coagulation activation and has been associated with coronary events.
It has also been inversely associated with wake after sleep onset as well as poor sleep quality and low sleep efficiency.
D-dimer is a byproduct of fibrinolysis which remains after a blood clot has been degraded.
It consists of two cross linked fragments of fibrinogen.
Elevated levels of D-dimer are a marker of thrombosis, as it might occur along atherosclerotic plaques in coronary blood vessels.
D-dimer will be measured by monoclonal sandwich ELISA, which measures in the 3.9 - 250 ng/ml range.
|
Week 27
|
|
Tissue Plasminogen Activator Levels
Prazo: Week 27
|
Tissue Plasminogen Activator is an endothelial lining protein that catalyzes the conversion of plasminogen into plasmin, which is responsible for the degradation of fibrin into soluble degradation products.
Caregivers of PWD showed higher levels of TPA.
A meta-analysis of cardiovascular disease risk and TPA indicated that levels greater than 13.5 ng/ml increased CVD risk by 50%.
|
Week 27
|
|
C-reactive Protein (CRP) Levels
Prazo: Week 27
|
C-reactive protein (CRP) is a non-specific marker of inflammation shown in many studies to be elevated in AD caregivers and to be associated with poor sleep.
High sensitivity CRP levels are consistently and independently associated with increased risk of cardiovascular events.
HS-CRP will be measured by an ELISA.
|
Week 27
|
|
Intercellular Adhesion Molecule-1 (ICAM-1)
Prazo: Week 27
|
Intercellular adhesion molecule-1 (ICAM-1) is found in leukocytes and endothelium and is involved in adhesion of leukocytes to and through the endothelium.
ICAM-1 is stimulated by the proinflammatory cytokines.
ICAM-1 may participate in atherogenesis by increasing monocyte transmigration into the arterial intima.
|
Week 27
|
|
IL-6, and TNFα Levels
Prazo: Week 27
|
It is becoming apparent that sleep and immunity are strongly related and that impairments in sleep increase these circulating cytokine levels.
Further, caregivers of Alzheimer's patients show both impaired sleep and elevated IL-6 and TNF-α.
Levels of IL-6, IL-1, and TNF-α are partially controlled by sleep, and also regulate sleep and many aspects of the immune response.
IL-6 and TNF-α are central mediators in the inflammatory process by regulating acute phase and coagulation protein, and inflammation plays a central role in the development and instability of atherosclerotic plaques.
|
Week 27
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Meredeth Rowe, RN, PhD, University Of South Florida
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de abril de 2012
Conclusão Primária (Real)
1 de julho de 2016
Conclusão do estudo (Real)
1 de julho de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
1 de março de 2012
Enviado pela primeira vez que atendeu aos critérios de CQ
6 de março de 2012
Primeira postagem (Estimativa)
9 de março de 2012
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
26 de outubro de 2016
Última atualização enviada que atendeu aos critérios de controle de qualidade
24 de outubro de 2016
Última verificação
1 de outubro de 2016
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 6201111800
- 1R01AG039495-01 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Sleep Behavioral Therapy A and NHMS
-
King's College LondonKings Health PartnersConcluídoDepressão | Transtorno Depressivo Maior | Depressão Unipolar | Depressão ModeradaReino Unido